As the most complicated and largest microecosystem, gut microbiota is increasingly recognized as a crucial contributor to intestinal homeostasis and host health, which has been demonstrated to function in nutrient absorption, metabolism, immune system maturation, and intestinal mucosal barrier. Notably, gut microbiota could extend their influences beyond the gastrointestinal system, affecting both near and far organ systems such as the brain and liver. Research has demonstrated that gut microbial dysbiosis in animals significantly contributes to various gastrointestinal diseases. For instance, gut microbial dysbiosis could affect intestinal permeability, allowing harmful substances and pathogens to cross the epithelial barrier, and causing intestinal inflammation or diarrhea. Additionally, gut microbiota dysbiosis has also been shown to play a crucial role in the development of inflammatory bowel disease and colorectal cancer. Therefore, it is essential to investigate and understand the gut microbial composition and structure in depth to effectively treat and prevent gastrointestinal diseases in animals.
In this Research Topic, we aim to explore the potential relationship between gut microbiome and gastrointestinal-related animal diseases by utilizing a multidisciplinary approach combining multi-omics techniques. We believe that this Research Topic will contribute to improving the understanding of pathogenesis and developing strategies to alleviate and prevent gastrointestinal-related animal diseases from a gut microbial perspective.
Specifically, studies focusing on gut microbiota in animal gastrointestinal diseases, including but not limited to the following, are highly welcome:
1. The changes of gut microbiome in gastrointestinal system diseases such as colitis, intestinal cancer, irritable bowel syndrome, Crohn's disease, bacterial, parasitic and viral diarrhea, etc
2. Multi-omics joint analysis in revealing the driving role and pathogenic mechanism of gut microbial dysbiosis in gastrointestinal system diseases
3. The development of novel therapeutic strategies, such as supplementing probiotics, prebiotics, polysaccharides, and natural products, to modulate the gut microbiota and intestinal function for alleviating and treating gastrointestinal-related diseases
4. The mechanisms by which gut microbiota modulates intestinal function and disease in animals, such as the production of metabolites, enzymes, and peptides
As the most complicated and largest microecosystem, gut microbiota is increasingly recognized as a crucial contributor to intestinal homeostasis and host health, which has been demonstrated to function in nutrient absorption, metabolism, immune system maturation, and intestinal mucosal barrier. Notably, gut microbiota could extend their influences beyond the gastrointestinal system, affecting both near and far organ systems such as the brain and liver. Research has demonstrated that gut microbial dysbiosis in animals significantly contributes to various gastrointestinal diseases. For instance, gut microbial dysbiosis could affect intestinal permeability, allowing harmful substances and pathogens to cross the epithelial barrier, and causing intestinal inflammation or diarrhea. Additionally, gut microbiota dysbiosis has also been shown to play a crucial role in the development of inflammatory bowel disease and colorectal cancer. Therefore, it is essential to investigate and understand the gut microbial composition and structure in depth to effectively treat and prevent gastrointestinal diseases in animals.
In this Research Topic, we aim to explore the potential relationship between gut microbiome and gastrointestinal-related animal diseases by utilizing a multidisciplinary approach combining multi-omics techniques. We believe that this Research Topic will contribute to improving the understanding of pathogenesis and developing strategies to alleviate and prevent gastrointestinal-related animal diseases from a gut microbial perspective.
Specifically, studies focusing on gut microbiota in animal gastrointestinal diseases, including but not limited to the following, are highly welcome:
1. The changes of gut microbiome in gastrointestinal system diseases such as colitis, intestinal cancer, irritable bowel syndrome, Crohn's disease, bacterial, parasitic and viral diarrhea, etc
2. Multi-omics joint analysis in revealing the driving role and pathogenic mechanism of gut microbial dysbiosis in gastrointestinal system diseases
3. The development of novel therapeutic strategies, such as supplementing probiotics, prebiotics, polysaccharides, and natural products, to modulate the gut microbiota and intestinal function for alleviating and treating gastrointestinal-related diseases
4. The mechanisms by which gut microbiota modulates intestinal function and disease in animals, such as the production of metabolites, enzymes, and peptides